Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · Real-Time Price · USD
31.06
+0.54 (1.77%)
At close: Jul 10, 2026, 4:00 PM EDT
31.50
+0.44 (1.42%)
After-hours: Jul 10, 2026, 7:59 PM EDT
Tango Therapeutics Revenue
Tango Therapeutics had revenue of $56.99M in the twelve months ending March 31, 2026, up 39.04% year-over-year. In the year 2025, Tango Therapeutics had annual revenue of $62.38M with 48.29% growth.
Revenue (ttm)
$56.99M
Revenue Growth
+39.04%
P/S Ratio
78.83
Revenue / Employee
$416,000
Employees
137
Market Cap
4.49B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 62.38M | 20.32M | 48.29% |
| Dec 31, 2024 | 42.07M | 5.54M | 15.17% |
| Dec 31, 2023 | 36.53M | 11.67M | 46.93% |
| Dec 31, 2022 | 24.86M | -12.18M | -32.89% |
| Dec 31, 2021 | 37.04M | 29.39M | 383.83% |
| Dec 31, 2020 | 7.66M | -16.99M | -68.94% |
| Dec 31, 2019 | 24.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.10B |
| Caris Life Sciences | 907.29M |
| NewAmsterdam Pharma Company | 22.57M |
| Relay Therapeutics | 10.68M |
| CRISPR Therapeutics AG | 4.10M |
TNGX News
- 12 days ago - Tango Therapeutics price target raised to $46 from $42 at Canaccord - TheFly
- 16 days ago - Tango Therapeutics upgraded to Buy from Hold at Jefferies - TheFly
- 19 days ago - Tango Therapeutics Appoints Robert Azelby to Board of Directors - GlobeNewsWire
- 4 weeks ago - Tango Therapeutics 18.2M share Secondary priced at $30.00 - TheFly
- 4 weeks ago - Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering - GlobeNewsWire
- 4 weeks ago - Tango Therapeutics price target raised to $66 from $27 at H.C. Wainwright - TheFly
- 4 weeks ago - Tango Therapeutics price target raised to $42 from $30 at Canaccord - TheFly
- 4 weeks ago - Tango Therapeutics announces $500M common stock offering - TheFly